Medindia

X

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology

Wednesday, October 31, 2007 General News J E 4
Advertisement
LAUSANNNE, Switzerland and CHIBA, Japan, October 31 Debiopharm Group (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions, andNanoCarrier Co., Ltd. (NanoCarrier) today announced the signature of aLicense and Supply Agreement for DACH-Platin Polymeric Micelle (Debio0507/NC-4016), MediCelle(TM) technology, owned by NanoCarrier, currently inlate preclinical development by Debiopharm for use in oncology. Phase Iclinical studies are expected to start in 2008 in Europe and / or USA.

Under the terms of the agreement:

- NanoCarrier grants Debiopharm an exclusive license, with the right tosublicense, develop and commercialize DACH-Platin Polymeric Micelle worldwideexcluding Japan.

- Debiopharm will provide NanoCarrier exclusively with the startingmaterial of DACH-platin, and NanoCarrier will manufacture and provideDACH-Platin Polymeric Micelle solely to Debiopharm.

- Debiopharm will cover costs related to the manufacture of DACH-PlatinPolymeric Micelle and will pay NanoCarrier an up-front and milestones, aswell as running royalties for the license.

- NanoCarrier will pay Debiopharm for the use of Debiopharm's data orintellectual property upon registration in Japan.

Debiopharm will be fully responsible for the development of DACH-PlatinPolymeric Micelle. The collaboration between the two companies started in2005, when NanoCarrier granted Debiopharm the exclusive option to license-ina DACH-platin-PEG-polyglutamic acid (DACH Platin MediCelle(TM)) fromNanoCarrier, for use in oncology.

About DACH-Platin Micelle

DACH-platin is an active metabolite of Oxaliplatin, which shows strongeranticancer activity. Oxaliplatin is an anticancer drug effective againstprogressive and relapsed colon cancer. However, it may cause severeperipheral neuropathy like numbness. Because of its hydrophobic feature, itwas difficult to formulate DACH-platin, but by using micellar nanoparticles,we believe we can develop a new, more effective DACH-platin anticancer drugwith possible lower side effects.

The basic technology of this formulation was invented by ProfessorKataoka of the University of Tokyo. The technology was licensed in fromTOUDAI TLO Ltd. The basic Japanese patent for DACH-platin micelle has beengranted as Patent No. 39955992 in May 2007.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialistthat in-licenses promising biologics and small molecule drug candidates.Debiopharm develops its products for global registration and maximumcommercial potential for out-licensing to pharmaceutical partners for salesand marketing.

Debiopharm independently funds the worldwide development of all of itsproducts while providing expertise in pre-clinical and clinical trials,manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharmhas developed three products: Eloxatin(R), Decapeptyl(R) and Trelstar(R) withglobal combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit:http://www.debiopharm.com.

About NanoCarrier Co., Ltd.

NanoCarrier is a biotech that focuses on the research and development ofdrugs primarily in the field of cancer with micellar nanoparticlestechnology. Micellar nanoparticles (also known as polymeric micelle) areformed from biocompatible block copolymers which consist of a hydrophilicpolymer, polyethyleneglycol (PEG), and a hydrophobic polymer, polyamino acidderivative.

By encapsulating drugs efficiently inside, micellar nanoparticles work asfunctional particles that stay in bloodstream for a long period of time anddeliver drugs preferentially to targeted sites, thus minimizing unfavourableside effects and improving the
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Bacchus Vascular Names Dennis Rosenberg as Vice Pr...
S
BME (BioMedical Enterprises, Inc.) Announces U.S. ...